CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1 G93A mice with a C57BL/6 background

Abstract The synthetic copper-containing compound, CuATSM, has emerged as one of the most promising drug candidates developed for the treatment of amyotrophic lateral sclerosis (ALS). Multiple studies have reported CuATSM treatment provides therapeutic efficacy in various mouse models of ALS without...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jeremy S. Lum, Mikayla L. Brown, Natalie E. Farrawell, Luke McAlary, Diane Ly, Christen G. Chisholm, Josh Snow, Kara L. Vine, Tim Karl, Fabian Kreilaus, Lachlan E. McInnes, Sara Nikseresht, Paul S. Donnelly, Peter J. Crouch, Justin J. Yerbury
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/c146cd7fdab24b4d90091d3aa58e739c
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!